| Authors: |
Damodaran S; The University of Texas MD Anderson Cancer Center, Houston, TX., Zhao F; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Deming DA; University of Wisconsin Carbone Cancer Center, Madison, WI., Mitchell EP; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA., Wright JJ; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; National Cancer Institute/Center for Biomedical Informatics & Information Technology, Rockville, MD., Williams PM; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope Comprehensive Cancer Center, Duarte, CA., Suga JM; Kaiser Permanente, Vallejo, CA., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Medical Center, Dallas, TX., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania Abramson Cancer Center, Division of Medical Oncology, Philadelphia, PA., Chen AP; Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Dana-Farber Cancer Institute/Harvard Medical School/Massachusetts General Hospital, Boston, MA. |
